TPG sold over 2 crore shares in two tranches at Rs 722 per share, a price that reflected a 1% discount to Thursday’s closing price.
Among the key buyers, Norway’s central bank, Norges Bank, acquired 11.5 lakh shares worth Rs 83 crore, signaling strong foreign institutional interest in the Indian pharmaceutical sector.
On the domestic front, several top mutual funds participated in the transaction:
— Nippon India Mutual Fund bought over 40 lakh shares for Rs 290 crore,
— Invesco Mutual Fund acquired 13.5 lakh shares worth Rs 97.5 crore, and
— Aditya Birla Sun Life Mutual Fund picked up 13.85 lakh shares for Rs 100 crore.Investor appetite appeared strong, as shares of Sai Life Sciences rallied 5% to close at Rs 765.85 on the BSE following the block deals.The stake reshuffle highlights the growing confidence of both global and domestic institutional investors in Sai Life’s long-term growth prospects amid the increasing relevance of India in the global pharma outsourcing ecosystem.
TPG held over 5.15 crore equity shares in the company as on March 31, 2025 through TPG Asia VII SF PTE Ltd, which accounts for a 24.73% stake in this smallcap company. The market capitalisation of the company is at Rs 15,230 crore. The stock of Sai Life Sciences was listed on the exchanges on December 18, 2024.
The stock has gained nearly 2% since its listing on December 18, 2024 and its returns on the year-to-date basis remain at 3%. This is an underperformance versus Nifty which has given returns of 6.6% and 5.7%, respectively.
Sai Life Sciences is a contract research, development, and manufacturing organisation (CRDMO) among listed Indian peers. The company has operations in the UK, the USA and Japan.
The company reported a 57% year-on-year profit in its Q4FY25 net profit at Rs 88 crore versus Rs 56 crore reported in the year ago period. The total revenue from operations in the January-March quarter of FY25 stood at Rs 589 crore, which was growth of 33% versus Rs 443 crore posted by the company in the corresponding quarter of the previous financial year.
According to Trendlyne data, shares of Sai Life Sciences are trading above its 50-day and 100-day simple moving averages (SMAs) of Rs 727 and Rs 715, respectively.
The stock has been quite volatile since the last 3 months. Its 1-year beta is at 1.4.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
By
